Author Of 1 Presentation
P0894 - One year real-life data on efficacy, safety, and retention of Teriflunomide in Cypriot patients with Relapsing-Remitting Multiple Sclerosis (ID 122)
Abstract
Background
Teriflunomide is a disease-modifying immunomodulatory drug with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase, with consequent inhibition of de novo pyrimidine synthesis and reduced lymphocyte proliferation. Oral teriflunomide is approved by EMA for the treatment of adult patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
Objectives
The purpose of our review was to assess for the first time the real-life efficacy, safety, and retention of Teriflunomide (TER) in Cypriot patients with RRMS, and to compare our results with those of other studies performed in similar populations.
Methods
Twenty-four adult patients were assessed retrospectively one year after the initiation of TER. Four patients (17%) received TER as the first Disease-Modifying Treatment (DMT), whereas twenty patients (83%) were converted to TER from other DMTs.
Results
At TER initiation, patients were of a mean age of 44 years (range: 21-63) and had a mean MS duration of 14 years (range: 0.5-30).
In treatment-naïve patients, mean Annual Relapse Rate (ARR) during the year before TER treatment was 0.5 (range: 0-1) and mean EDSS progression 0.5 (range: 0-1.5). Twelve months after TER, mean ARR remained stable (p=0.423) whereas EDSS progression was reduced by 25% (p=0.057).
In DMT-converted patients, mean Annual Relapse Rate (ARR) during the year before TER treatment was 0.4 (range: 0-3) and mean EDSS progression 0.3 (range: 0-1.5). Twelve months after TER, both mean ARR and EDSS progression remained stable (p= 0.111 and p= 0.241 respectively).
TER retention rate was 79%. Five patients (21 %) discontinued TER: Three due to disease progression, one due to extreme neck pain and one due to lactose intolerance.
Most frequent ADRs were infections (26% of patients), increased ALT (21% of patients) and gastrointestinal discomfort (21% of patients).
Conclusions
Teriflunomide proved to be equally effective to previously used DMTs in our DMT-converted patients, whereas it significantly reduced disease progression in our treatment-naïve patients. ADRs were mostly mild and transient leading to high retention to therapy.
Our results are in line with those of other studies demonstrating the efficacy, safety, and retention of Teriflunomide in similar populations.
Presenter Of 1 Presentation
P0894 - One year real-life data on efficacy, safety, and retention of Teriflunomide in Cypriot patients with Relapsing-Remitting Multiple Sclerosis (ID 122)
Abstract
Background
Teriflunomide is a disease-modifying immunomodulatory drug with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase, with consequent inhibition of de novo pyrimidine synthesis and reduced lymphocyte proliferation. Oral teriflunomide is approved by EMA for the treatment of adult patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
Objectives
The purpose of our review was to assess for the first time the real-life efficacy, safety, and retention of Teriflunomide (TER) in Cypriot patients with RRMS, and to compare our results with those of other studies performed in similar populations.
Methods
Twenty-four adult patients were assessed retrospectively one year after the initiation of TER. Four patients (17%) received TER as the first Disease-Modifying Treatment (DMT), whereas twenty patients (83%) were converted to TER from other DMTs.
Results
At TER initiation, patients were of a mean age of 44 years (range: 21-63) and had a mean MS duration of 14 years (range: 0.5-30).
In treatment-naïve patients, mean Annual Relapse Rate (ARR) during the year before TER treatment was 0.5 (range: 0-1) and mean EDSS progression 0.5 (range: 0-1.5). Twelve months after TER, mean ARR remained stable (p=0.423) whereas EDSS progression was reduced by 25% (p=0.057).
In DMT-converted patients, mean Annual Relapse Rate (ARR) during the year before TER treatment was 0.4 (range: 0-3) and mean EDSS progression 0.3 (range: 0-1.5). Twelve months after TER, both mean ARR and EDSS progression remained stable (p= 0.111 and p= 0.241 respectively).
TER retention rate was 79%. Five patients (21 %) discontinued TER: Three due to disease progression, one due to extreme neck pain and one due to lactose intolerance.
Most frequent ADRs were infections (26% of patients), increased ALT (21% of patients) and gastrointestinal discomfort (21% of patients).
Conclusions
Teriflunomide proved to be equally effective to previously used DMTs in our DMT-converted patients, whereas it significantly reduced disease progression in our treatment-naïve patients. ADRs were mostly mild and transient leading to high retention to therapy.
Our results are in line with those of other studies demonstrating the efficacy, safety, and retention of Teriflunomide in similar populations.